Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.50 |
| ▸ | TNKS | O95271 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24123996 | 0.89 | QDPR (0.45) | QDPRTNKSPARP1TNKS2SLC6A2 | |
| SCHEMBL1823938 | 0.88 | SLC6A2 (0.41) | QDPRSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL13242901 | 0.87 | QDPR (0.44) | QDPRTNKSPARP1TNKS2ESR1 | |
| SCHEMBL24309521 | 0.87 | QDPR (0.51) | QDPRTNKSPARP1TNKS2ESR1 | |
| SCHEMBL24123862 | 0.84 | QDPR (0.41) | QDPRTNKSPARP1TNKS2ESR1 | |
| SCHEMBL22063677 | 0.84 | QDPR (0.47) | QDPRTNKSPARP1TNKS2HTR2C | |
| SCHEMBL10078397 | 0.81 | QDPR (0.53) | QDPRSLC6A2SLC6A4SLC6A3ESR1 | |
| SCHEMBL28296842 | 0.81 | NPC1 (0.37) | QDPRSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL3157843 | 0.79 | NPY5R (0.39) | NPY5R | |
| SCHEMBL2606127 | 0.79 | QDPR (0.55) | QDPRTNKSPARP1TNKS2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2017097927-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-15 | — | — | WO | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20100144701-A1 | Modulators of CB1 Receptors | 7TM PHARMA A/S (DK) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | ACHE, AADAC, ATL3 | QDPR 1656/4885TNKS 447/4885PARP1 1739/4885 |
| US-20100144701-A1 | Modulators of CB1 Receptors | CNR1, CNR2, GPR6 | QDPR 2143/4885TNKS 4601/4885PARP1 4043/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | QDPR 677/4885TNKS 2707/4885PARP1 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.